The estimated Net Worth of Robert J Gibson is at least $40 mil dollars as of 24 February 2021. Mr Gibson owns over 300 units of Scopus Biopharma stock worth over $0 and over the last 4 years he sold SCPS stock worth over $0. In addition, he makes $40,000 as Vice Chairman y Sec. & Treasurer at Scopus Biopharma.
Sign up
Mr Gibson SCPS stock SEC Form 4 insiders trading
Mr has made over 1 trades of the Scopus Biopharma stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 300 units of SCPS stock worth $2,814 on 24 February 2021.
The largest trade he's ever made was buying 300 units of Scopus Biopharma stock on 24 February 2021 worth over $2,814. On average, Mr trades about 300 units every 0 days since 2021. As of 24 February 2021 he still owns at least 300 units of Scopus Biopharma stock.
You can see the complete history of Mr Gibson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Robert J. Gibson biography
Robert J. Gibson is the Vice Chairman, Sec. & Treasurer at Scopus Biopharma.
What is the salary of Mr Gibson?
As the Vice Chairman y Sec. & Treasurer of Scopus Biopharma, the total compensation of Mr Gibson at Scopus Biopharma is $40,000. There are 2 executives at Scopus Biopharma getting paid more, with Ira Scott Greenspan having the highest compensation of $180,000.
What's Mr Gibson's mailing address?
Robert's mailing address filed with the SEC is C/O SCOPUS BIOPHARMA INC., 420 LEXINGTON AVENUE, SUITE 300, NEW YORK, NY, 10170.
Insiders trading at Scopus Biopharma
Over the last 4 years, insiders at Scopus Biopharma have traded over $0 worth of Scopus Biopharma stock and bought 21,190 units worth $148,408 . The most active insiders traders include Ira Scott Greenspan, Joshua R Lamstein y Robert J Gibson. On average, Scopus Biopharma executives and independent directors trade stock every 12 days with the average trade being worth of $0. The most recent stock trade was executed by Ira Scott Greenspan on 27 August 2021, trading 900 units of SCPS stock currently worth $4,473.
What does Scopus Biopharma do?
Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
What does Scopus Biopharma's logo look like?
Complete history of Mr Gibson stock trades at Scopus Biopharma
Scopus Biopharma executives and stock owners
Scopus Biopharma executives and other stock owners filed with the SEC include:
-
Ira Scott Greenspan,
Sr. Advisor & Director -
Dr. Morris C. Laster,
Co-Chairman & CEO -
Daniel J. Politzer C.F.A.,
CFO & COO -
Robert J. Gibson,
Vice Chairman, Sec. & Treasurer -
Alan D. Horsager Ph.D.,
Pres?of?Immuno-Oncology and Pres & CEO of Olimmune Inc. -
Dr. Alan M. Horsager Ph.D.,
Pres -
David Silberg,
Sr. Advisor -
Ashish Pradip Sanghrajka,
Pres & Director -
Robert J Gibson,
Vice Chairman -
Ira Scott Greenspan,
Executive Committee Chairman -
Joshua R Lamstein,
Chairman -
Paul Hopper,
Director